Landfar Bio-medicine: The company's stock trading may be subject to delisting risk warning
I'm PortAI, I can summarize articles.
According to the announcement from Landfar Bio-medicine, the company expects its net profit for the fiscal year 2024 and net profit after deducting non-recurring gains and losses to both be negative, and the operating income after deduction is expected to be below 300 million yuan. According to Article 9.3.1 (1) of the Shenzhen Stock Exchange Stock Listing Rules, after the disclosure of the company's 2024 annual report, the trading of the company's stock may be subject to delisting risk warning (the stock abbreviation will be prefixed with "*ST")
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments